Compare Bristol-Myers Squibb Co (BMY) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $32.63. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| BMY | TMF | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $62.37 | $44.14 |
52-Week Low | $42.60 | $31.85 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
TMF, a leveraged ETF tracking long-term US Treasuries, trades at $32.81, down 1.83% today. Technical indicators are bearish overall, with moving averages signaling strong selling pressure, though oscillators show some bullish momentum. The stock lacks traditional fundamental metrics like P/E or revenue due to its ETF structure, relying instead on underlying bond performance and interest rate trends.
Outlook remains volatile, driven by Federal Reserve policy shifts and bond market fluctuations. Risks include daily leverage decay and interest rate sensitivity. Analyst sentiment is mixed, with some seeing opportunity at bond market lows, while others caution against long-term holds due to amplified losses in rising rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
